UCB SA (UCB.BR) Stock Fundamental Analysis
EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
UCB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. UCB has only an average score on both its financial health and profitability. UCB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
UCB had positive earnings in the past year.
UCB had a positive operating cash flow in the past year.
UCB had positive earnings in each of the past 5 years.
Each year in the past 5 years UCB had a positive operating cash flow.
1.2 Ratios
UCB's Return On Assets of 6.14% is in line compared to the rest of the industry. UCB outperforms 60.00% of its industry peers.
Looking at the Return On Equity, with a value of 10.62%, UCB is in line with its industry, outperforming 56.00% of the companies in the same industry.
UCB has a Return On Invested Capital (8.79%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 14.77%.
The 3 year average ROIC (4.35%) for UCB is below the current ROIC(8.79%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROIC | 8.79% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
Looking at the Profit Margin, with a value of 17.31%, UCB is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
UCB's Profit Margin has been stable in the last couple of years.
The Operating Margin of UCB (23.31%) is better than 66.00% of its industry peers.
UCB's Operating Margin has declined in the last couple of years.
UCB has a Gross Margin of 71.52%. This is comparable to the rest of the industry: UCB outperforms 60.00% of its industry peers.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UCB is creating some value.
UCB has about the same amout of shares outstanding than it did 1 year ago.
UCB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, UCB has an improved debt to assets ratio.
2.2 Solvency
UCB has an Altman-Z score of 4.05. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.05, UCB is in the better half of the industry, outperforming 64.00% of the companies in the same industry.
UCB has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as UCB would need 3.29 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.29, UCB is in the better half of the industry, outperforming 66.00% of the companies in the same industry.
UCB has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.30, UCB is doing good in the industry, outperforming 64.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 4.05 |
ROIC/WACC1.17
WACC7.5%
2.3 Liquidity
UCB has a Current Ratio of 1.36. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of UCB (1.36) is comparable to the rest of the industry.
UCB has a Quick Ratio of 1.36. This is a bad value and indicates that UCB is not financially healthy enough and could expect problems in meeting its short term obligations.
UCB has a Quick ratio (0.99) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
UCB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.86% yearly.
The Revenue has grown by 17.14% in the past year. This is quite good.
UCB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.60% yearly.
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
3.2 Future
The Earnings Per Share is expected to grow by 26.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, UCB will show a quite strong growth in Revenue. The Revenue will grow by 10.98% on average per year.
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y26.6%
Revenue Next Year16.66%
Revenue Next 2Y14.56%
Revenue Next 3Y13.56%
Revenue Next 5Y10.98%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 34.65, UCB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as UCB.
When comparing the Price/Earnings ratio of UCB to the average of the S&P500 Index (27.41), we can say UCB is valued slightly more expensively.
With a Price/Forward Earnings ratio of 23.26, UCB is valued on the expensive side.
UCB's Price/Forward Earnings is on the same level as the industry average.
UCB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 35.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.65 | ||
| Fwd PE | 23.26 |
4.2 Price Multiples
UCB's Enterprise Value to EBITDA is on the same level as the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as UCB.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.48 | ||
| EV/EBITDA | 16.43 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as UCB's earnings are expected to grow with 34.53% in the coming years.
PEG (NY)0.71
PEG (5Y)N/A
EPS Next 2Y37.44%
EPS Next 3Y34.53%
5. Dividend
5.1 Amount
With a yearly dividend of 0.56%, UCB is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.00, UCB has a dividend in line with its industry peers.
With a Dividend Yield of 0.56, UCB pays less dividend than the S&P500 average, which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
24.32% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.32%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EBR:UCB (7/14/2025, 5:35:30 PM)
172.55
+1.6 (+0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.65%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap33.56B
Analysts75.83
Price Target211.8 (22.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP24.32%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.65 | ||
| Fwd PE | 23.26 | ||
| P/S | 5.46 | ||
| P/FCF | 36.48 | ||
| P/OCF | 27.02 | ||
| P/B | 3.35 | ||
| P/tB | 69.2 | ||
| EV/EBITDA | 16.43 |
EPS(TTM)4.98
EY2.89%
EPS(NY)7.42
Fwd EY4.3%
FCF(TTM)4.73
FCFY2.74%
OCF(TTM)6.39
OCFY3.7%
SpS31.63
BVpS51.56
TBVpS2.49
PEG (NY)0.71
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROCE | 10.38% | ||
| ROIC | 8.79% | ||
| ROICexc | 10.16% | ||
| ROICexgc | 50.51% | ||
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% | ||
| FCFM | 14.95% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.43 | ||
| Cap/Depr | 50.23% | ||
| Cap/Sales | 5.23% | ||
| Interest Coverage | 8.96 | ||
| Cash Conversion | 59.86% | ||
| Profit Quality | 86.39% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 4.05 |
F-Score9
WACC7.5%
ROIC/WACC1.17
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y26.6%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
Revenue Next Year16.66%
Revenue Next 2Y14.56%
Revenue Next 3Y13.56%
Revenue Next 5Y10.98%
EBIT growth 1Y178.99%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year142.1%
EBIT Next 3Y54.39%
EBIT Next 5Y34.43%
FCF growth 1Y106.74%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y63.21%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%